FDA approves 1st eosinophilic esophagitis treatment

The FDA approved the first treatment for eosinophilic esophagitis, a chronic inflammatory disorder, according to a May 20 news release.

The treatment, Dupixent, was approved May 20 to treat eosinophilic esophagitis in adults and pediatric patients 12 and older weighing at least 88 pounds.

Dupixent is a monoclonal antibody that helps stop part of the inflammatory pathway of the esophagus in those with the disease, the release said.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast